CLSA analysts downgraded Dr. Reddy's Laboratories shares, trading on both BSE (DRRD:IN) and NYSE (NYSE:RDY), from a Hold to an Underperform rating, adjusting the price target from INR1,140 to INR1,090 ...

CLSA upgraded the stock to 'hold', citing recent corrections, despite inventory losses and weaker refining margins.

The firm expects mid-single-digit price erosion in generic drugs and heightened competition for key medications, potentially ...

Brokerage firm Nuvama has highlighted concerns about BPCL's weak refining margin environment and LPG under-recoveries, which are impacting its earnings. Additionally, the high capital expenditure ...

Finance companies' performance in the first half of 2025 is expected to be impacted by high credit costs due to unsecured credit. But it is seen normalising in the second half on underwriting ...

Vikash Kumar Jain, India Strategist and Head of Research at CLSA, predicts 2025 will be a year of consolidation for Indian markets. He noted that the consolidation trend, which began in October, could ...

Shares of Zomato surged as much as 7.27% to reach INR 261.75 during the intraday trading session on the BSE today (January 16 ...

The brokerage firm has also added Zomato to its high conviction outperform list, saying the recent correction is a buying ...

CLSA has initiated coverage on Hyundai Motor India with an 'Outperform' rating and a target price of Rs 2,155, citing strong ...

CLSA reaffirmed Bharti Airtel as Indias top telecom pick, citing robust growth potential and 5G expansion. Indus Towers, Tata Communications, and others also received mixed ratings, while Vodafone ...

Bank Mandiri (IDX: BMRI) is projected to become Indonesia’s most profitable bank by 2025, surpassing Bank Rakyat Indonesia ...